Receptor Tyrosine Kinase Phosphorylation Pattern-Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment
文献类型：期刊论文
| 作者 | Sun, Xiaoxiao; Song, Qiaoling; He, Li; Yan, Lei; Liu, Jingli; Zhang, Qing ; Yu, Qiang
|
| 刊名 | MOLECULAR CANCER THERAPEUTICS
 |
| 出版日期 | 2016-10-01 |
| 卷号 | 15期号:10页码:2508-2520 |
| ISSN号 | 1535-7163 |
| DOI | 10.1158/1535-7163.MCT-15-0735 |
| 文献子类 | Article |
| 英文摘要 | Receptor tyrosine kinases (RTK) are key signaling molecules in regulating cancer cell growth and are important cancer drug targets. Despite the success of specific RTK-targeting therapy in certain cancer treatments, the overall response rates are limited to the drug target-stratified populations. We have systematically studied RTK activations in a panel of cancer cell lines, primary cancers, and cancer xenografts and found that different combinations of RTKs were activated in different cancer cells regardless of their tissue origins. Combinations of specific RTK inhibi tors (RTKi) preferentially inhibited proliferation of the cancer cells with corresponding RTK activation profiles. We also found that the activations of RTKs were regulated by both cell-autonomous and environment-dependent mechanisms and demonstrated that inhibition of all activated RTKs was essential to completely block cancer cell proliferation. In addition, c-Myc downregulation was identified as an indicator for the effectiveness of the RTKi combination treatments. Our findings demonstrated that the RTK activation profile is a valid biomarker for diagnosis and stratification of cancers, and a corresponding combination of RTKis is a promising strategy to treat cancers, particularly the single RTKi therapy-resistant cancers, selectively and effectively. (C) 2016 AACR. |
| WOS关键词 | TUMOR-CELL LINES ; C-MYC ; EXPRESSION LEVELS ; BREAST-CANCER ; GROWTH ; INHIBITOR ; THERAPY ; MET ; REQUIREMENTS ; CARCINOMA |
| 资助项目 | China Ministry of Science and Technology Key New Drug Creation and Manufacturing Program[2013ZX09102015] ; China Ministry of Science and Technology Key New Drug Creation and Manufacturing Program[2013ZX10002010-009] ; National Natural Science Foundation of China[81302792] ; National Natural Science Foundation of China[81373447] ; National Natural Science Foundation of China[91413121] ; National Natural Science Foundation of China[91213304] ; China National Key Basic Research Program[2012CB910704] ; China National Key Basic Research Program[2013CB910904] |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| 出版者 | AMER ASSOC CANCER RESEARCH |
| WOS记录号 | WOS:000385636300023 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/275880]  |
| 专题 | 药理学第一研究室 |
| 通讯作者 | Yu, Qiang |
| 作者单位 | Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, Shanghai, Peoples R China |
| 推荐引用方式 GB/T 7714 | Sun, Xiaoxiao,Song, Qiaoling,He, Li,et al. Receptor Tyrosine Kinase Phosphorylation Pattern-Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment[J]. MOLECULAR CANCER THERAPEUTICS,2016,15(10):2508-2520. |
| APA | Sun, Xiaoxiao.,Song, Qiaoling.,He, Li.,Yan, Lei.,Liu, Jingli.,...&Yu, Qiang.(2016).Receptor Tyrosine Kinase Phosphorylation Pattern-Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment.MOLECULAR CANCER THERAPEUTICS,15(10),2508-2520. |
| MLA | Sun, Xiaoxiao,et al."Receptor Tyrosine Kinase Phosphorylation Pattern-Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment".MOLECULAR CANCER THERAPEUTICS 15.10(2016):2508-2520. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。